ABSTRACT BACKGROUND: Previous studies have implicated the cyclic adenosine monophosphate/protein kinase A pathway as well as FosB and dynorphin-B expression mediated by dopamine D 1 receptor stimulation in the development of 3,4-dihydroxyphenyl-L-alanine (L-DOPA)-induced dyskinesia. The magnitude of these molecular changes correlates with the intensity of dyskinesias. The calcium-binding protein downstream regulatory element antagonistic modulator (DREAM) binds to regulatory element sites called DRE in the DNA and represses transcription of target genes such as c-fos, fos-related antigen-2 (fra-2), and prodynorphin. This repression is released by calcium and protein kinase A activation. Dominant-active DREAM transgenic mice (daDREAM) and DREAM knockout mice (DREAM 2/2 ) were used to define the involvement of DREAM in dyskinesias. METHODS: Dyskinesias were evaluated twice a week in mice with 6-hydroxydopamine lesions during long-term L-DOPA (25 mg/kg) treatment. The impact of DREAM on L-DOPA efficacy was evaluated using the rotarod and the cylinder test after the establishment of dyskinesia and the molecular changes by immunohistochemistry and Western blot. RESULTS: In daDREAM mice, L-DOPA-induced dyskinesia was decreased throughout the entire treatment. In correlation with these behavioral results, daDREAM mice showed a decrease in FosB, phosphoacetylated histone H3, dynorphin-B, and phosphorylated glutamate receptor subunit, type 1 expression. Conversely, genetic inactivation of DREAM potentiated the intensity of dyskinesia, and DREAM 2/2 mice exhibited an increase in expression of molecular markers associated with dyskinesias. The DREAM modifications did not affect the kinetic profile or antiparkinsonian efficacy of L-DOPA therapy. CONCLUSIONS: The protein DREAM decreases development of L-DOPA-induced dyskinesia in mice and reduces L-DOPA-induced expression of FosB, phosphoacetylated histone H3, and dynorphin-B in the striatum. These data suggest that therapeutic approaches that activate DREAM may be useful to alleviate L-DOPA-induced dyskinesia without interfering with the therapeutic motor effects of L-DOPA.
Despite extensive research focused on discovering therapeutic alternatives, the dopamine precursor molecule 3,4-dihydroxyphenyl-L-alanine (L-DOPA), remains the most effective and widely used noninvasive therapy for Parkinson's disease. Chronic administration of L-DOPA and disease progression cause the appearance of abnormal involuntary movements known as dyskinesias in most patients. L-DOPA-induced dyskinesia (LID) is causally linked with hyperstimulation of dopamine D 1 receptors (D1Rs) located on direct pathway medium spiny neurons of the severely denervated striatum (1) (2) (3) . In the dopamine-depleted striatum, L-DOPA activates a cyclic adenosine monophosphate (cAMP)-dependent signaling cascade via protein kinase A (PKA) activation (4, 5) , resulting in abnormally increased phosphorylation of cAMP-regulated phosphoprotein of 32 kDa (DARPP-32) and activation of the Ras/extracellular signal-regulated kinase signaling pathway in the same neurons (1, (6) (7) (8) (9) . These events induce transcriptional changes resulting in increased expression of FosB, phospho-(Ser10)-acetyl-(Lys14)-histone-3 (P-AcH3), and dynorphin-B (10, 11) .
In addition, the increased activation of the cAMP/PKA/ DARPP-32 pathway observed in dyskinesia induces persistent phosphorylation of the alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA) glutamate receptor subunit, type 1 (GluR1) at Ser845 (6,7) via protein phosphatase-1 inhibition, enhancing excitatory glutamatergic transmission in D1R-containing neurons and increasing N-methyl-D-aspartate receptor (NMDAR) activation (12) (13) (14) (15) . Enhanced synaptic transmission in LID has been associated with altered redistribution and trafficking of D1Rs (16) along with a massive accumulation of postsynaptic density protein 95 (PSD-95) in the synaptic membrane (17) . It has been shown that PSD-95 modulates LID in rats and monkeys by its direct interaction with D1Rs (18) . In addition, D1R-mediated activation of adenylyl cyclase/PKA triggers calcium entry through voltage-dependent calcium channels (19) , and treatment with the L-type calcium channel antagonist isradipine diminishes dyskinesias (20) , further supporting the idea that calcium entry into direct pathway striatal neurons after D1R stimulation contributes to LID.
Despite the progress made in recent years, the intracellular signaling mechanism downstream of D1R-PKA-dependent activation is not fully established. The downstream regulatory element antagonist modulator (DREAM), also known as calsenilin and KChIP3, is a calcium-binding protein that mediates calcium-dependent and cAMP-dependent transcriptional responses (21, 22) . In striatal neurons, moderate levels of DREAM are present in the neuropil and cell soma (23) (24) (25) . In basal conditions, DREAM binds to a regulatory element called DRE, located downstream from the transcription initiation site, repressing the transcription of target genes, including prodynorphin, c-fos, and Fos-related antigen-2 (fra-2) (26, 27) . Repression mediated by DREAM is reversed by calcium and by its PKA-dependent interaction with phospho-CREM, the cAMP-response element modulator (26, (28) (29) (30) . Outside the nucleus, DREAM directly interacts with several proteins (31) , including NR1 subunit (32) and PSD-95 (33) , inhibiting NMDAR function and its surface expression.
Based on these observations and on our previous data demonstrating a close association between LID and overexpression of FosB and dynorphin-B (1,10), we propose that DREAM, located downstream of D1R-dependent cAMP/PKA activation, plays an important role in the cascade of molecular events leading to LID. If this hypothesis is true, DREAM could provide a site for intervention to improve the efficacy of L-DOPA treatment, while preventing the upregulation of target genes associated with dyskinesia. To investigate this possible role of DREAM in LID, we used DREAM knockout and dominant active DREAM transgenic mice in a mouse model of dyskinesias.
METHODS AND MATERIALS

Animals
This study was carried out in transgenic mice 3-6 months old expressing a dominant active mutant DREAM (daDREAM) (34, 35) or in DREAM-deficient mice (22, 36) . Both genetically modified animals and wild-type (WT) controls were maintained in a C57BL/6 background. In the daDREAM mice, expression of the transgene, a bi-cistronic construct including the daDREAM mutant, an internal ribosome entry site sequence, and the lacZ reporter, was driven by the calcium/calmodulindependent protein kinase type II alpha promoter (37) . The transgenic line (JN26) used in this study has a telencephalicspecific expression with high levels of transgene expression in the striatum ( Figure S1 in Supplement 1). Homozygous daDREAM and DREAM knockout (DREAM 2/2 ) mice were derived from mating the corresponding heterozygous mice. Genotyping was performed by polymerase chain reaction (PCR) as described previously (35, 36) . Bacterial artificial chromosome-transgenic D1R-tomato mice (38) were used to study DREAM striatal localization. All animal procedures followed guidelines from the European Union Council Directive (86/609/European Economic Community), and experimental protocols were approved by the Consejo Superior de Investigaciones Científicas Ethics Committee.
6-Hydroxydopamine Lesion and L-DOPA Treatment
Animals received unilateral stereotaxic injections (2 3 2 mL) of 6-hydroxydopamine (6-OHDA) hydrobromide (20 mmol/L, containing .02% ascorbic acid; Sigma-Aldrich, St. Louis, Missouri) as described previously (39) . After 3 weeks of recovery, mice received a daily intraperitoneal injection of 25 mg/kg of L-DOPA methyl ester (Sigma-Aldrich) 20 min after benserazide hydrochloride (10 mg/kg; Sigma-Aldrich) for a 3-week period.
Behavioral Analysis
Locomotor Activity and Motor Coordination. Horizontal and vertical activity and total distance traveled were recorded in mice as described previously (40) . Motor coordination was measured in the Rota-Rod (Ugo Basile, Varese, Italy) following an accelerating protocol, with increasing speed from 4-40 rpm over a 5-min period as described (41) . Mice were tested in six consecutive trials 20 min apart. Measurements were done before injection of 6-OHDA (naïve); 3 weeks after lesion (parkinsonian); and during L-DOPA treatment (dyskinetic) on day 9, 24 hours after the last L-DOPA injection to avoid exhaustion and the peak dyskinesia.
Dyskinetic Score. Dyskinesias induced by L-DOPA were evaluated twice a week for 3 weeks, 40 minutes after L-DOPA injection, using a 0-4 severity scale as described previously (1, 38) . The time course of L-DOPA response for each genotype was evaluated on day 20, for 1 min every 20 min during 160 min after L-DOPA injection.
Cylinder Test. The cylinder test was performed according to Espadas et al. (42) before the 6-OHDA lesion; 3 weeks after lesion; and on day 17 the chronic L-DOPA treatment, 140 min after L-DOPA injection to avoid dyskinetic symptoms. Spontaneous ipsilateral and contralateral forelimb touches to the cylinder were counted for 3 min to assess forelimb asymmetry.
Immunohistochemistry and Image Analysis
Mice were killed 1 hour after the last L-DOPA injection, and immunohistochemistry studies were performed as described previously (43, 44) using the following antibodies: tyrosine hydroxylase (TH) (1:1000; Millipore, Temecula, California), FosB (1:7500; Santa Cruz Biotechnology, Santa Cruz, California), dynorphin-B 1-29 (leumorphin) (1:10;000; Serotec, Oxford, United Kingdom), P-AcH3 (1:1500; Upstate Cell Signaling Solutions, Lake Placid, New York), DREAM (FL-214) (1:250; Santa Cruz Biotechnology), and Hoechst (1 mg/mL; SigmaAldrich).
The extent of dopaminergic lesions was quantified using Neurolucida software (MBF Bioscience, Williston, Vermont), DREAM Protein Reduces Dyskinesia in Mice depicting the border of striatal areas with complete loss of TH-immunoreactive fibers with a 4 3 lens using seven to nine serial rostrocaudal sections per animal. Quantification of FosB, P-AcH3, and dynorphin-B immunoreactivity was carried out as described previously (10, 45) .
Reverse Transcription Quantitative PCR (RT-qPCR)
Total RNA from isolated striata was extracted using the Illustra RNAspin kit (GE Healthcare Europe, Barcelona, Spain). Quantitative PCR for DREAM and TH was performed with TaqMan Assay on Demand primers and the TaqMan Universal PCR Master Mix, No AmpErase UNG (Applied Biosystems, Madrid, Spain). The PCR reactions were performed in triplicate in a 7900HT Fast Real-Time PCR System (Applied Biosystems). Expression of target genes was normalized using the 18S expression and calculated using the delta-delta Ct method (46) .
Western Blot
Animals were sacrificed by decapitation 30 min after the last L-DOPA injection, and striatal tissue was dissected and homogenized. Western blot analysis was performed with primary antibodies against phospho-Ser845-GluR1 (1:7500; Millipore), TH (1:4000; Millipore), and β-actin (1:50,000; Sigma-Aldrich) as a loading control. Blots were developed by chemiluminescence (ECL Plus; GE Healthcare, Little Chalfont, United Kingdom) and quantified by densitometry.
Statistical Analysis
Behavioral data and quantifications of immunolabeling were analyzed by two-way analysis of variance followed by Newman-Keuls post hoc test. The extent of the dopaminergic lesion and DREAM messenger RNA (mRNA) expression were analyzed by one-way analysis of variance. Differences were considered statistically significant at p , .05.
RESULTS
Basal Locomotor Activity and Motor Coordination Are Normal in DREAM Mutant Mice
Although no morphologic differences were evident between genotypes, we carried out spontaneous locomotor activity and rotarod tests before the 6-OHDA lesion to rule out any motor ) potentiates L-DOPA-induced dyskinesia. Time course of appearance of dyskinetic symptoms is shown: Limb, ORF, Axial, and Loc. Movements were evaluated 40 min after L-DOPA (25 mg/kg) administration at the indicated days. daDREAM mice showed a lower dyskinetic score for limb and orofacial dyskinesia and for axial dystonia compared with WT mice, whereas inactivation of DREAM in DREAM 2/2 mice significantly increased these dyskinetic symptoms. No statistically significant differences were found for locomotive dyskinesia. Data are expressed as mean 6 SEM. Two-way analysis of variance with repeated measures followed by Newman-Keuls test showed significant differences for genotype [F 2,190 , DREAM knockout; daDREAM, dominant-active DREAM; Limb, limb dyskinesia; Loc, locomotive dyskinesia; ORF, orofacial dyskinesia; WT, wild-type.
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Biological Psychiatry January, 2015; 77:95-105 www.sobp.org/journalimpairment in the mutant mice that could interfere with L-DOPA behavioral studies. In the absence of any external challenge, daDREAM, DREAM 2/2 , and WT mice showed similar horizontal and vertical activity, as indicated by the number of beam breaks measured in a multicage activity meter system ( Figure 1A ,B). Ambulatory activity measured as total distance traveled was also similar among the three genotypes ( Figure 1C ). Over time, as the mice habituated to the environment, the number of beam breaks and the distance traveled diminished, with a similar profile in all three genotypes. No statistically significant differences between genotypes were found in the rotarod test ( Figure 1D ). All animals achieved a significant increase (p , .001) in the latency to fall from the rotating rod at the sixth and last trial compared with the first trial, showing a similar capacity of motor learning in the rotarod. Taken together, these results indicated that alterations in DREAM expression do not modify spontaneous locomotor activity or motor coordination.
DREAM Modulates L-DOPA-Induced Dyskinesias
To examine the role of DREAM in dyskinesias in hemiparkinsonian/6-OHDA-lesioned mice, we assessed axial dystonia and forelimb, orofacial, and locomotive dyskinesia in daDREAM, DREAM
2/2
, and corresponding WT littermates 40 min after L-DOPA administration. The L-DOPA injections were given daily, and assessments were done twice a week, as described previously (1, 10) .
In WT mice, LID symptoms were already apparent at the beginning of the treatment and progressively increased to reach a plateau in the second week of L-DOPA administration ( Figure 2 ). The daDREAM mice showed a significant reduction in dyskinetic movements, in particular for limb (p , .001) and orofacial (p , .001) symptoms, as well as for axial dystonia (p , 0.001) compared with WT littermates. Meanwhile, the DREAM 2/2 mice showed a significant enhancement in limb (p , .05) and orofacial (p , .01) dyskinesia as well as axial dystonia (p , .05). These changes were apparent from the first day of L-DOPA administration and lasted over the entire 3-week treatment. No difference in locomotive dyskinesia was observed among genotypes, indicating that DREAM modification does not compromise the motor stimulant effect of L-DOPA.
We calculated the global dyskinetic score of daDREAM and DREAM 2/2 mice and evaluated the time course of L-DOPA response in both genotypes. Although dyskinesia was observed in both daDREAM and WT mice, the total score achieved by daDREAM mice was significantly lower (p , .001) compared with WT mice for all time points evaluated ( Figure 3A) . On the other hand, the total dyskinetic score was higher in DREAM 2/2 mice compared with WT littermates. The difference was statistically significant (p , .05), although it was smaller than the difference observed between the daDREAM and the WT mice.
To look for differences in the kinetic profile of L-DOPA responses among genotypes, we determined the duration of the dyskinetic response and the peak severity of the symptoms by evaluating the time course of L-DOPA response in daDREAM and DREAM 2/2 mice on day 20 of L-DOPA administration ( Figure 3B ). Dyskinetic symptoms were scored for 1 min every 20 min during the 160 min following L-DOPA administration. Dyskinesia was evident at 20 min, peaked between 40 and 60 min, and declined significantly at 100 min after L-DOPA before disappearing at 140 min for both genotypes. Although the time course of L-DOPA response was similar in both groups of mice, daDREAM mice exhibited significantly lower dyskinesia compared with WT mice throughout the entire duration of the L-DOPA response. Finally, there were no statistically significant differences between DREAM 2/2 and WT mice in the duration of the L-DOPA response. As in daDREAM mice, the response was evident 20 min after L-DOPA and disappeared after 140 min. However, a difference was again observed in the intensity of the dyskinetic symptoms, which were stronger in DREAM 
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To exclude that the extent of the dopaminergic lesion in the three genotypes was different, which could influence the results, we assessed the percentage of striatal volume with a complete loss of TH-immunoreactive fibers for each group of animals ( Figure 3C ). We found no statistically significant difference between groups (daDREAM, 44.2% 6 2%; DREAM 2/2 , 48.7% 6 2%; and WT, 46.2% 6 2%).
Antiparkinsonian Effect of L-DOPA Is Maintained in DREAM Mutant Mice
To rule out that the different dyskinetic score induced by L-DOPA in DREAM mutant mice is not due to an altered motor response to L-DOPA in these mice, we carried out the cylinder and rotarod tests to measure the antiparkinsonian effect of L-DOPA (42, 47) . In the cylinder test, naïve mice used both forelimbs similarly, whereas lesioned mice showed a significant (p , .001) asymmetry in forelimb use ( Figure 4A ). As expected, L-DOPA significantly (p , .001) recovered the contralateral paw use. Importantly, no significant differences were observed among the three genotypes, indicating that the genetic manipulation of DREAM does not affect the motor impairment induced by the lesion or the therapeutic effect of L-DOPA. Similar results were observed with the rotarod, which evaluates motor coordination ( Figure 4B ), strengthening the data from the cylinder test and further confirming that modifications in DREAM do not alter the antiparkinsonian efficacy of L-DOPA.
DREAM Is Expressed in Direct and Indirect Striatal Projection Neurons
Previous studies demonstrated that DREAM is expressed in the striatum and substantia nigra (23) (24) (25) . Using naïve bacterial artificial chromosome-transgenic D1R-tomato mice to differentiate direct from indirect pathway neurons, we observed moderate DREAM signal in both D1R-positive (red fluorescence) and D1R-negative (no fluorescence) medium spiny neurons ( Figure 5A ). This immunolabeling was preferentially nuclear but was also evident in the cytoplasm and in the neuropil. Quantification experiments of DREAM carried out by RT-qPCR demonstrated that L-DOPA treatment to sham or lesioned animals did not modify DREAM mRNA expression in the striatum or in the substantia nigra ( Figure 5B ). RT-qPCR was also used to measure TH mRNA in the substantia nigra in the same animals to confirm the efficacy of 6-OHDA lesion ( Figure 5C ).
DREAM Regulates Key Molecular Determinants of LID
Several studies have correlated the increased levels of FosB, P-AcH3, and dynorphin-B in the dorsolateral lesioned striatum with the appearance of LID (1, 11, 48) . We evaluated the effect of the genetic modification of DREAM on the striatal levels of these markers after chronic L-DOPA administration in hemiparkinsonian mice. The number of FosB-positive neurons was threefold lower in the lesioned striatum of daDREAM transgenic mice (p , .001) and just slightly increased in DREAM 2/2 mice (p , .01) compared with WT mice (Figure 6A,B) . The presence of histone H3 phosphorylated on Ser10 and acetylated on Lys14 was significantly modified in the striatum ipsilateral to the lesion with a 2.5-fold decrease in the number of P-AcH3-positive nuclei in daDREAM mice (p , .001) and a 1.5-fold increase in DREAM 2/2 mice compared with WT mice (p , .001) (Figure 6C,D) . Finally, scanning of the dynorphin-Bpositive area, including cytoplasm and neuropil, revealed a 39% reduction (p , .01) and a 65% increase (p , .001) relative to the total area scanned in daDREAM and DREAM 2/2 mice, respectively ( Figure 6E,F) . No statistically significant differences were found in any of these molecular markers in the unlesioned striatum of daDREAM, DREAM 2/2 , and WT mice, which served as a negative control for these experiments. As an additional control for the specificity of these changes, we verified that L-DOPA-induced changes were strictly restricted to the completely denervated striatal area ( Figure S2 in Supplement 1), as we have shown before (2, 10, 38) . These results indicate that genetic manipulation of DREAM does not DREAM Protein Reduces Dyskinesia in Mice modify the expression pattern of the molecular markers of dyskinesia in mice. These findings correlate well with our behavioral results and implicate DREAM in the regulation of FosB, P-AcH3, and dynorphin-B levels.
LID-Associated Phosphorylation of GluR1 Is Attenuated in daDREAM Mice
It is well documented that in the striatum of 6-OHDA-lesioned mice (6) and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) lesion monkeys (49) , chronic L-DOPA administration results in PKA-dependent hyperphosphorylation of the GluR1 subunit of the glutamate AMPA receptor at serine 845. We examined whether the genetic modification of DREAM modifies the phosphorylation state of GluR1 (P-GluR1) induced by L-DOPA. Analysis of striatal extracts showed that L-DOPA treatment induces an increase in P-GluR1 levels in WT lesioned mice, as expected. This increase was evident also in DREAM 2/2 mice. In contrast, overexpression of DREAM in daDREAM mice inhibited the hyperphosphorylation of GluR1 induced by L-DOPA ( Figure 7A ). In parallel, measurement of levels of TH protein confirmed a similar efficacy of the 6-OHDA lesion in all samples ( Figure 7B ).
DISCUSSION
These studies provide evidence that the DREAM protein plays a modulatory role in LID in mice and in the underlying molecular changes within the denervated striatum. Overexpression of a dominant active version of DREAM in transgenic mice dramatically reduced LID, whereas genetic inactivation of DREAM increased dyskinetic symptoms. In strict correspondence with the behavioral observations, molecular markers of dyskinesia induced by chronic L-DOPA treatment, including FosB, dynorphin-B, P-AcH3, and P-GluR1, were decreased in daDREAM mice but increased in DREAM 2/2 mice. Importantly, modifications in DREAM did not alter the kinetic profile or the antiparkinsonian efficacy of L-DOPA, suggesting that modulation of DREAM function could serve as an intervention target in therapies designed to alleviate LID without interfering with the beneficial effects of L-DOPA treatment.
In agreement with previous observations in naïve DREAM 2/2 (36,50) and daDREAM (51) adult mutant mice, spontaneous locomotor activity and motor coordination were indistinguishable from WT littermates, suggesting that the differences observed in LID are not due to any motor impairment but rather to the modifications related to DREAM levels. Moreover, dyskinetic differences among genotypes after L-DOPA treatment are not due to alterations of the kinetic profile of L-DOPA by DREAM because all animals showed a similar duration of the L-DOPA response. Mutant mice show similar motor performance skills in the cylinder and rotarod tests, demonstrating that the antiparkinsonian effect of L-DOPA is preserved in mutant animals despite DREAM modifications. The DREAM protein is a multifunctional calcium-binding protein (52) that acts as a transcriptional repressor to regulate activity-dependent gene expression through direct interaction with regulatory sites in the DNA (26) . Our data show that DREAM is present in the nucleus of striatal projection neurons. In these neurons, increased expression of FosB and dynorphin-B after L-DOPA treatment correlates with dyskinesias in patients with Parkinson's disease (53, 54) , in MPTP- DREAM Protein Reduces Dyskinesia in Mice treated monkeys (55, 56) , and in 6-OHDA-treated rats (48) and mice (1, 10, 38) . Transcriptional repression of FosB and prodynorphin genes in daDREAM mice could be directly related to the observed reduction in development of LID.
Correlating with the behavioral response to L-DOPA, our results show that overexpression of daDREAM diminishes FosB and dynorphin-B expression induced by L-DOPA in denervated striatal neurons, whereas genetic inactivation of DREAM induces the opposite effect. The small increase of FosB and dynorphin-B expression observed in the striatum of DREAM-deficient mice after L-DOPA is in agreement with similar increases observed previously in the spinal cord of DREAM 2/2 mice (36). By binding to DRE sites located in the 5 0 -untranslated sequence downstream from the TATA box, DREAM represses the transcription of the immediate early genes fra-2 and c-fos as well as prodynorphin (26, 27) .
Although not previously studied, our data indicate that DREAM may also repress FosB, consistent with the presence of two DRE sites in this gene (57) . Dynorphin-B expression is also regulated by D1R activation (58) and by binding of Fos/Jun heterodimers to an AP-1 site in the prodynorphin gene (59) . Overexpression of FosB after L-DOPA treatment induces a concomitant increase of dynorphin-B expression in the 6-OHDA lesioned striatum (48) . Our data support the notion that DREAM exerts a synergistic double effect: directly, blocking prodynorphin transcription by anchoring to its DRE site, and indirectly, diminishing FosB expression and resulting in dynorphin-B downregulation via AP-1. The nontranscriptional effects of DREAM have been shown to regulate cell function and synaptic activity, mostly through various specific protein-protein interactions (31) . The list of target proteins includes cationic channels (60), membrane receptors (32, 61) , and membrane docking proteins (33) . Because a wide variety of mechanisms underlie synaptic changes associated with LID, including abnormal dendritic spine increases in denervated dopamine D 2 receptor-containing striatal neurons (38) involved in corticostriatal synapses (62) , several additional mechanisms could be related to DREAM-mediated changes in LID based on its presence in the cell body as discussed below.
In addition to D1R stimulation, NMDAR activation plays an important role in dyskinesia; treatment with NMDAR antagonists such as MK-801 or amantadine completely abolishes LID (63, 64) . The DREAM protein has been shown to diminish NMDAR activation (32, 33) . In cultured neurons, DREAM knockdown with small interfering RNAs significantly enhanced NMDAR-mediated currents, whereas overexpression of DREAM reduced NMDAR activation and its presence in the plasma membrane, indicating that DREAM modulates NMDAR function. Taken together, these data correlate well with our dyskinetic behavioral results. Inactivation of DREAM, which potentiates NMDAR-mediated currents, potentiates dyskinesia, whereas overexpression of DREAM, which inhibits NMDAR function, decreases dyskinesia. It is possible that the inhibitory role of DREAM in LID reported here could be partially related to the negative regulation exerted by DREAM on NMDAR by directly interacting with the NR1 subunit and preventing full activation of the NMDAR complex as shown in cultured hippocampal neurons (32) . On the other hand, the documented capacity of DREAM to bind PSD-95 (33), impairing the recruitment of PSD-95 by D1Rs (18) , could contribute to the observed reduction of LID. Disruption of the NMDAR-PSD-95 complex increases LID (14) , probably by making PSD-95 available for interaction with D1Rs in the synaptic membrane. Displacement of the normal PSD-95 interactome from D1Rs owing to increased DREAM levels could explain the decrease in dyskinesia in daDREAM mice.
Acetylated histone H3 is associated with active chromatin and gene transcription (65) , and this effect is synergistically potentiated by phosphorylation (66) . Because phosphoacetylation of histone H3 correlates with the intensity of dyskinesias (6, 10, 11, 67) , the presence of increased phosphoacetylated histone H3 in DREAM-deficient animals is consistent with increased dynorphin-B and FosB expression and with increased LID. On the contrary, in the presence of the daDREAM repressor, we observed decreased P-AcH3, dynorphin-B, FosB, and LID, as expected. In line with these observations, DREAM has been shown to inhibit transcription by blocking the CREB-CBP histone acetylase complex (29) . On the other hand, histone H3 phosphorylation depends on the stimulation of the D1R pathway (10) . Although it is possible that this phosphorylation occurs through the D1R/cAMP/PKA/ DARPP-32 signaling pathway, it could also be mediated by the reported NMDAR-DREAM interaction through the NR1 receptor subunit (32) .
Although a direct DREAM and AMPA receptor interaction has not been described, it is possible that an indirect interaction occurs because overexpression of DREAM significantly blocked L-DOPA-induced phosphorylation of the PKA substrate AMPA receptor subunit GluR1 at Ser845. The phosphorylation of GluR1 after L-DOPA administration is correlated with more recent work from our laboratory (38) showing dendritic spine regrowth in denervated striatal areas. Spine regrowth leads to a recruitment of AMPA receptors to the postsynaptic density (68) (69) (70) in an activity-dependent manner (i.e., L-DOPA activation) because in basal conditions this recruitment is inactive. This finding is in line with our Western blot experiments, which revealed similar levels of GluR1 phosphorylation in basal conditions in all mutant mice, consistent with previous work (33) .
Finally, DREAM overexpression could control LID development through the regulation of voltage-dependent calcium channels. It has been shown that blockade of L-type calcium channels using the antagonist isradipine decreases dyskinetic symptoms (20) , whereas overexpression of DREAM reduces the expression of the Cav1.2 gene encoding the L-type calcium channel (52) and decreases calcium permeability by direct protein-protein interaction with the L-type and the T-type channel complexes (31, 71, 72) .
In conclusion, this study demonstrates the inhibitory role of DREAM in LID as evidenced by reduction of dyskinetic symptoms in daDREAM mice and a potentiation in DREAM 2/2 mice. In addition, we demonstrate that this action occurs at least in part by transcriptional repression of target genes, although nontranscriptional mechanisms could also be involved. Dynorphin-B and possibly FosB expression are regulated by DREAM, which represses their transcription by anchoring to DRE sites in the DNA and reducing LID. In addition, outside the nucleus, DREAM could directly interact with the NR1 subunit and PSD-95, regulating activation of NMDAR and D1Rs (Figure 8 ). The findings we describe in this article validate DREAM as a novel therapeutic target against LID, and we propose that specific modulators of DREAM could be useful in alleviating L-DOPA-induced dyskinesias without interfering with the antiparkinsonian effect of L-DOPA. However, other, as yet uncharacterized transcriptional and nontranscriptional targets of DREAM could also be important, directly or indirectly, in the regulation of LID. Future genomewide analysis during LID establishment in daDREAM and DREAM 2/2 mice might expand understanding of the role of DREAM in LID. and WT mice, whereas DREAM overexpression blocks L-DOPA-induced GluR1-phosphorylation. (B) The TH levels were quantified to confirm the efficacy of 6-hydroxydopamine lesion, and no statistically significant differences were found among genotypes. Relative intensities versus loading control actin (normalized to WT Sham) were analyzed by two-way analysis of variance followed by Newman-Keuls test. 
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